Evidence map›Paper›PMID 29635374›Full record

ArticleGigaScience2018

Genome-wide determination of on-target and off-target characteristics for RNA-guided DNA methylation by dCas9 methyltransferases.

Lin Lin, Yong Liu, Fengping Xu, Jinrong Huang, Tina Fuglsang Daugaard, Trine Skov Petersen, Bettina Hansen, Lingfei Ye, Qing Zhou, Fang Fang and 13 more

Open access · goldAbstract read
In one paragraph

Article in GigaScience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 119 citations in OpenAlex.

  1. Trial
  2. The landscape and trajectory of global CRISPR therapeutics.Molecular therapy. Nucleic acids · 2026
    Review
  3. Epigenetic insights and innovations for overcoming barriers in CAR-T cell therapy for cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  4. Review
  5. Review
  6. Epigenetic editing: from concept to clinic.Nature reviews. Drug discovery · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. All-in-one vectors for epigenetic CRISPR inhibition ofMolecular therapy. Methods & clinical development · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 5 institutions in 3 countries.

Lin LinDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Yong LiuDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Fengping XuBGI-Shenzhen, Shenzhen 518083, China.
Jinrong HuangBGI-Shenzhen, Shenzhen 518083, China.
Tina Fuglsang DaugaardDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Trine Skov PetersenDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Bettina HansenDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Lingfei YeBGI-Shenzhen, Shenzhen 518083, China.
Qing ZhouBGI-Shenzhen, Shenzhen 518083, China.
Fang FangBGI-Shenzhen, Shenzhen 518083, China.
Ling YangBGI-Shenzhen, Shenzhen 518083, China.
Shengting LiDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Lasse FløeDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Kristopher Torp JensenDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Ellen ShrockDepartment of Genetics, Harvard Medical School, Boston, MA, USA.
Fang ChenBGI-Shenzhen, Shenzhen 518083, China.
Huanming YangBGI-Shenzhen, Shenzhen 518083, China.
Jian WangBGI-Shenzhen, Shenzhen 518083, China.
Xin LiuBGI-Shenzhen, Shenzhen 518083, China.
Xun XuBGI-Shenzhen, Shenzhen 518083, China.
Lars BolundDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Anders Lade NielsenDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Yonglun LuoDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Aarhus University · DKBGI Group (China) · CNChina National GeneBank · CNUniversity of Copenhagen · DKHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Fusion of DNA methyltransferase domains to the nuclease-deficient clustered regularly interspaced short palindromic repeat (CRISPR) associated protein 9 (dCas9) has been used for epigenome editing, but the specificities of these dCas9 methyltransferases have not been fully investigated. Findings: We generated CRISPR-guided DNA methyltransferases by fusing the catalytic domain of DNMT3A or DNMT3B to the C terminus of the dCas9 protein from Streptococcus pyogenes and validated its on-target and global off-target characteristics. Using targeted quantitative bisulfite pyrosequencing, we prove that dCas9-BFP-DNMT3A and dCas9-BFP-DNMT3B can efficiently methylate the CpG dinucleotides flanking its target sites at different genomic loci (uPA and TGFBR3) in human embryonic kidney cells (HEK293T). Furthermore, we conducted whole genome bisulfite sequencing (WGBS) to address the specificity of our dCas9 methyltransferases. WGBS revealed that although dCas9-BFP-DNMT3A and dCas9-BFP-DNMT3B did not cause global methylation changes, a substantial number (more than 1000) of the off-target differentially methylated regions (DMRs) were identified. The off-target DMRs, which were hypermethylated in cells expressing dCas9 methyltransferase and guide RNAs, were predominantly found in promoter regions, 5΄ untranslated regions, CpG islands, and DNase I hypersensitivity sites, whereas unexpected hypomethylated off-target DMRs were significantly enriched in repeated sequences. Through chromatin immunoprecipitation with massive parallel DNA sequencing analysis, we further revealed that these off-target DMRs were weakly correlated with dCas9 off-target binding sites. Using quantitative polymerase chain reaction, RNA sequencing, and fluorescence reporter cells, we also found that dCas9-BFP-DNMT3A and dCas9-BFP-DNMT3B can mediate transient inhibition of gene expression, which might be caused by dCas9-mediated de novo DNA methylation as well as interference with transcription. Conclusion: Our results prove that dCas9 methyltransferases cause efficient RNA-guided methylation of specific endogenous CpGs. However, there is significant off-target methylation indicating that further improvements of the specificity of CRISPR-dCas9 based DNA methylation modifiers are required.

Indexed as

CpG IslandsCRISPR-Cas SystemsDNA MethylationGenomeHEK293 CellsHumansMethyltransferasesRNA, Guide, CRISPR-Cas SystemsMethyltransferasesRNA, Guide, CRISPR-Cas Systems

Identifiers

PMID29635374
PMCPMC5888497
OpenAlexW2793659744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.